Travere Therapeutics delivered a strong performance in Q4 2025, with U.S. net product sales of FILSPARI reaching $103.3 million, marking a 108% growth year-over-year. The company also reported a net income of $2.7 million and an EPS of $0.03 for the quarter, a significant improvement from a net loss in the prior year. Strategic progress includes the FDA review of FILSPARI for FSGS and resumed enrollment for the HARMONY Study of pegtibatinase.

Travere Therapeutics delivered strong Q1 2025 results, driven by the successful commercial launch of FILSPARI for IgAN, with significant increases in net product sales and a substantial reduction in net loss compared to the previous year. The company also made significant progress towards expanding FILSPARI's indications and geographic reach.

Travere Therapeutics delivered a strong performance in Q4 2024, with total revenue reaching $74.787 million, significantly up from the previous year. The company's net product sales, particularly from FILSPARI, were a key driver of this growth. Despite an operating loss, the company maintained a healthy cash position and is advancing its key programs, including the sNDA submission for FILSPARI in FSGS and the restart of enrollment for pegtibatinase.

Travere Therapeutics reported strong Q3 2024 financial results, highlighted by the full FDA approval of FILSPARI and a meaningful increase in demand. The company's commercial team delivered strong sales growth of FILSPARI in the U.S. Travere is actively preparing for potential sNDA submissions and expanding FILSPARI's availability in Europe through its partner CSL Vifor.

Travere Therapeutics reported a successful second quarter in 2024, marked by significant growth in FILSPARI sales and new patient start forms. The company is preparing for the potential full approval of FILSPARI in IgAN, and making strides in global expansion and advancing its pipeline programs.

Travere Therapeutics reported strong first quarter 2024 results, marked by new highs in demand and revenue for FILSPARI in IgAN. The FDA granted Priority Review for FILSPARI's sNDA, and the European Commission granted conditional marketing authorization. The company is also progressing with the HARMONY Study of pegtibatinase in HCU.

Travere Therapeutics reported Q4 2023 net product sales of $39.9 million, driven by FILSPARI. The company is advancing its pipeline, including a Phase 3 study for pegtibatinase. The company had $566.9 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

Travere Therapeutics reported Q3 2023 financial results, highlighted by the growth in FILSPARI prescriptions and sales, advancements in clinical programs, and the completion of the sale of the bile acid product portfolio. Net product sales reached $33.9 million, with FILSPARI contributing $8 million.

Travere Therapeutics reported a total revenue of $59.7 million for the second quarter of 2023, including $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue. The company's cash, cash equivalents, and marketable securities totaled $491.3 million as of June 30, 2023.

Travere Therapeutics reported a net product sales of $50.3 million for Q1 2023, including $3.0 million from FILSPARI. Total revenue reached $57.0 million, with $6.7 million from licensing and collaboration. The company's cash, cash equivalents, and marketable securities totaled $561.5 million as of March 31, 2023.

Travere Therapeutics reported a total revenue of $55.9 million for Q4 2022, with net product sales of $52.3 million. The company's net loss for the quarter was $65.8 million, or $1.03 per basic share. FILSPARI received FDA accelerated approval, and the company is advancing its clinical programs with key milestones expected in 2023.

Travere Therapeutics reported a net product sales of $50.8 million and total revenue of $53.5 million for the third quarter of 2022. The company's cash, cash equivalents and marketable securities totaled $506.3 million as of September 30, 2022. The EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe and a new PDUFA target action date for sparsentan in IgAN was set for February 17, 2023.

Travere Therapeutics reported a total revenue of $54.2 million for the second quarter of 2022, consisting of $51.0 million in net product sales and $3.2 million in licensing and collaboration revenue. The company's cash, cash equivalents, and marketable securities totaled $553.2 million as of June 30, 2022.

Travere Therapeutics reported total revenue of $48.5 million for Q1 2022, with net product sales of $46.4 million and licensing and collaboration revenue of $2.0 million. The company's net loss was $76.0 million, or $1.20 per basic share. As of March 31, 2022, cash, cash equivalents, and marketable securities totaled $603.4 million.

Travere Therapeutics reported Q4 2021 financial results, featuring a rise in net product sales to $54.6 million compared to $51.0 million in the same period of 2020. However, the company experienced a net loss of $51.6 million, or $0.84 per basic share, compared to a net loss of $121.6 million, or $2.37 per basic share for the same period in 2020.

Travere Therapeutics reported net product sales of $54.2 million for the third quarter of 2021. The company is on track for an NDA submission for accelerated approval in the first quarter of next year.

Travere Therapeutics reported net product sales of $54.6 million for the second quarter of 2021. The company is on track to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021. The pivotal PROTECT Study of sparsentan in IgA nephropathy is on track to report topline data from the interim 36-week proteinuria endpoint in August 2021.

Travere Therapeutics reported net product sales of $47.4 million for the first quarter of 2021. The company is engaging with regulators in pursuit of submissions for accelerated approval for sparsentan in focal segmental glomerulosclerosis (FSGS).

Travere Therapeutics reported Q4 2020 net product sales of $51.0 million, compared to $46.7 million for the same period in 2019. The company's research and development expenses for the fourth quarter of 2020 were $38.4 million, compared to $36.4 million for the same period in 2019. Net loss for the fourth quarter of 2020 was $121.6 million, or $2.37 per basic share, compared to a net loss of $30.3 million for the same period in 2019.

Retrophin, Inc. reported a 15% increase in net product sales, reaching $51.1 million for the third quarter of 2020. The company is progressing with its clinical trials for sparsentan in FSGS and IgAN, and has an agreement to acquire OT-58 for classical homocystinuria treatment.

Retrophin reported an eight percent increase in net product sales, reaching $48 million in the second quarter of 2020. The company's cash and equivalents totaled $457 million following a $109 million common stock offering. Enrollment in the Phase 3 PROTECT Study is ahead of schedule, and topline proteinuria data from both pivotal studies in FSGS and IgAN are now anticipated in 2021.

Retrophin's first quarter 2020 financial results showed net product sales increased to $47.8 million compared to $39.6 million for the same period in 2019. The company achieved the critical milestone of enrolling the first 190 patients in its pivotal DUPLEX Study of sparsentan in FSGS. Net income for the first quarter of 2020 was $0.8 million, compared to a net loss of $41.0 million for the same period in 2019.

Retrophin reported fourth-quarter net product sales of $46.7 million, compared to $43.8 million for the same period in 2018. The company's focus on advancing sparsentan in FSGS and IgA nephropathy pivotal studies is progressing, with topline data expected in the coming years.